Catheter Precision, Inc. announced on September 30, 2025, that it received notification from the United States Patent and Trademark Office (USPTO) of the allowance for issuance of two new patents. These patents will add to the company's intellectual property portfolio.
One patent is titled 'Methods of Ventricular Arrhythmia Localization Using a 3D Model,' which enhances the VIVO technology and will be assigned to Kardionav, the company's joint venture. The second patent, 'Neurostimulation Devices and Methods,' is aimed at improving cardiac ventricular function, particularly in heart failure patients, and will be assigned to Cardionomix, a majority-owned subsidiary.
David Jenkins, CEO, commented that the confirmation of additional intellectual property through these patent issuances creates value for the company's different technology areas. This solidifies the belief that Catheter Precision's products can be unique in a competitive medical device marketplace, supporting its ongoing strategy to pursue new applications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.